Generic Drugs
- All
- News
- Videos
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report
As the patent for semaglutide, the active ingredient in Ozempic, nears expiry, Indian pharmaceutical companies are preparing to launch cheaper generic versions.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
US Revives Drug Origin Debate, Cites Indian Exports
US renewed a push to require country-of-origin labeling on prescription drugs, citing temporary restrictions on pharmaceutical exports during the Covid pandemic by India as evidence that America's drug supply remains vulnerable to foreign disruptions
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
Hyderabad-Based Pharmaceutical Gets US Nod For Generic ADHD Drug: Why This Matters And What It Means
ADHD is a neurodevelopmental condition that affects both children and adults. It is characterised by symptoms such as difficulty concentrating, impulsive behaviour and hyperactivity.
-
Trump May Exclude Generic Drugs From Tariffs. Good News For India?
The Donald Trump administration has dropped plans to impose tariffs on generic drugs from foreign countries, following months of debate over whether to impose taxes on the majority of medications prescribed in the US.
-
Trump's 100% Tariff On Pharma Will Not Impact Generic Makers: Industry Leaders
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
-
Trump Declares 100% Tariff On Pharma Imports From October 1, India May Be Hit
US President Donald Trump has announced tariffs of up to 100 per cent on imports of branded and patented pharmaceutical products from October 1. India's pharmaceuticals sector, one of the most dependent domestic industries on trade with America.
-
HIV-Prevention Drug To Be Available For Rs 3,500 A Year From 2027
Generic versions of a groundbreaking injectable HIV-prevention drug should be available for $40 or Rs 3,548 a year in more than 100 countries from 2027, Unitaid and the Gates Foundation said Wednesday.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report
As the patent for semaglutide, the active ingredient in Ozempic, nears expiry, Indian pharmaceutical companies are preparing to launch cheaper generic versions.
-
India-US Trade Deal Likely To Offer Tariff Relief On Exported Medicines
India's pharmaceutical industry has welcomed the interim trade agreement framework between India and the US, which offers tariff relief on medicines and several other Indian exports.
-
US Revives Drug Origin Debate, Cites Indian Exports
US renewed a push to require country-of-origin labeling on prescription drugs, citing temporary restrictions on pharmaceutical exports during the Covid pandemic by India as evidence that America's drug supply remains vulnerable to foreign disruptions
-
Indian Drugmakers Recall Medicines In The US Over Manufacturing Issues
Indian drugmakers Sun Pharmaceutical Industries and Cipla have recalled certain products from the US market due to manufacturing-related issues, according to the latest update from the US Food and Drug Administration (USFDA).
-
Hyderabad-Based Pharmaceutical Gets US Nod For Generic ADHD Drug: Why This Matters And What It Means
ADHD is a neurodevelopmental condition that affects both children and adults. It is characterised by symptoms such as difficulty concentrating, impulsive behaviour and hyperactivity.
-
Trump May Exclude Generic Drugs From Tariffs. Good News For India?
The Donald Trump administration has dropped plans to impose tariffs on generic drugs from foreign countries, following months of debate over whether to impose taxes on the majority of medications prescribed in the US.
-
Trump's 100% Tariff On Pharma Will Not Impact Generic Makers: Industry Leaders
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
-
Trump Declares 100% Tariff On Pharma Imports From October 1, India May Be Hit
US President Donald Trump has announced tariffs of up to 100 per cent on imports of branded and patented pharmaceutical products from October 1. India's pharmaceuticals sector, one of the most dependent domestic industries on trade with America.
-
HIV-Prevention Drug To Be Available For Rs 3,500 A Year From 2027
Generic versions of a groundbreaking injectable HIV-prevention drug should be available for $40 or Rs 3,548 a year in more than 100 countries from 2027, Unitaid and the Gates Foundation said Wednesday.
